Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

(2021) Claire M. Gelfman et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration

(2021) Frank G. Holz et al.   OPHTHALMOLOGY

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

(2021) Neil M Bressler et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration

(2021) Ryo Mukai et al.   PLoS One

Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

(2021) Nancy M. Holekamp et al.   OPHTHALMOLOGY

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR

(2020) Masahito Ohji et al.   ADVANCES IN THERAPY

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration

(2020) Derek Kunimoto et al.   OPHTHALMOLOGY

HAWK and HARRIER

(2020) Pravin U. Dugel et al.   OPHTHALMOLOGY

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

(2020) Jayashree Sahni et al.   JAMA Ophthalmology

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

(2020) Arshad M. Khanani et al.   JAMA Ophthalmology

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents

(2020) Rebecca N. Evans et al.   JAMA Ophthalmology

Adeno-associated virus vector as a platform for gene therapy delivery

(2019) Dan Wang et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

(2019) Jörg T Regula et al.   EMBO Molecular Medicine

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

(2019) Pravin U. Dugel et al.   OPHTHALMOLOGY

Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective

(2019) Ashish Sharma et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives

(2019) Thierry Bordet et al.   DRUG DISCOVERY TODAY

Innovative therapies for neovascular age-related macular degeneration

(2019) Hasenin Al-Khersan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models

(2018) Emese Szabó et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration

(2018) Yuanyuan Liu et al.   MOLECULAR THERAPY

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

(2018) Rufino Silva et al.   OPHTHALMOLOGY

Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration

(2018) Ruslan Grishanin et al.   MOLECULAR THERAPY

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

(2016) Jörg T Regula et al.   EMBO Molecular Medicine

Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy

(2015) Andreas Plückthun   Annual Review of Pharmacology and Toxicology

Molecular pathogenesis of retinal and choroidal vascular diseases

(2015) Peter A. Campochiaro   PROGRESS IN RETINAL AND EYE RESEARCH

Gene Therapy of ABCA4-Associated Diseases

(2015) A. Auricchio et al.   Cold Spring Harbor Perspectives in Medicine

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

(2013) Usha Chakravarthy et al.   LANCET

Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON

(2013) Soraya Rofagha et al.   OPHTHALMOLOGY

Ocular gene therapy: introduction to the special issue

(2012) R R Ali   GENE THERAPY

HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

(2012) Michael A. Singer et al.   OPHTHALMOLOGY

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

(2012) Daniel F. Martin et al.   OPHTHALMOLOGY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

Vascular Endothelial Growth Factor A in Intraocular Vascular Disease

(2012) Joan W. Miller et al.   OPHTHALMOLOGY

Myositis Ossificans

(2011) Deborah A. Martin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal Antibodies

(2010) Leo Borras et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

(2009) Geeta A. Lalwani et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY